In conversation with Thomas Wellner

As CEO of closely held Therapure Biopharma, Thomas Wellner is lifting the contract development and manufacturing organization (CDMO) out of the ashes of Hemosol, which fell into receivership in 2005 and was acquired in 2007 by privately owned Catalyst Fund Limited Partnership, a private equity fund in Toronto.  With a global focus on business development [...]

Amorfix suspends blood testing for vCJD

Amorfix Life Sciences (TSX:AMF) has suspended development to commercialize its blood test for variant Creutzfeldt-Jakob disease (vCJD) after two new recently developed versions of the test did not yield positive results. “Although we were able to achieve unprecedented sensitivity with brain prions diluted into blood, we have been unable to detect blood prions with the [...]